Xanthoxyletin blocks the RANK/RANKL signaling pathway to suppress the growth of human pancreatic cancer cells

Zhang, Xin; Li, Luming; Wu, Yan

doi:10.2478/acph-2023-0024

Abstract

Xanthoxyletin is a vital plant-derived bioactive coumarin. It has been shown to exhibit anticancer effects against different human cancers. Nonetheless, the anticancer effects of xanthoxyletin against human pancreatic cancer cells have not been evaluated. Against this backdrop, the present study was designed to evaluate the anticancer effects of xanthoxyletin in human pancreatic cancer cells and to decipher the underlying molecular mechanisms. The results revealed a significant (p < 0.05) upregulation of receptor activator of NF-kappaB (RANK), receptor activator of NF-kappaB ligand (RANKL) and osteoprotegerin (OPG) in human pancreatic tissues and cell lines at both transcriptional and translational levels. The administration of pancreatic cancer cells with xanthoxyletin diminished the viability of Capan-2 cells in a concentration-dependent manner and led to a significant decline in RANK, RANKL, and OPG expression. Silencing of RANK and xanthoxyletin treatment declined the viability of Capan-2 pancreatic cancer cells via induction of apoptosis. However, pancreatic cancer cells overexpressing RANK could rescue the growth inhibitory effects. Collectively, xanthoxyletin targets the RANK/RANKL signaling pathway in pancreatic cancer cells to induce cell apoptosis and may prove to be an important lead molecule.

References

P. Rawla, T. Sunkara and V. Gaduputi, Epidemiology of pancreatic cancer: Global trends, etiology and risk factors, World J. Oncol. 10(1) (2019) 10–27; https://doi.org/10.14740/wjon1166
Search in Google Scholar Back to article
W. Wu, X. He, L. Yang, Q. Wang, X. Bian, J. Ye, Y. Li and L. Li, Rising trends in pancreatic cancer incidence and mortality in 2000-2014, Clin Epidemiol. 10 (2018) 789–797; https://doi.org/10.2147/CLEP.S160018
Search in Google Scholar Back to article
M. Ilic and I. Ilic, Epidemiology of pancreatic cancer, World J. Gastroenterol. 22(44) (2016) 9694–9705; https://doi.org/10.3748/wjg.v22.i44.9694
Search in Google Scholar Back to article
J. P. Neoptolemos, J. Kleeff, P. Michl, E. Costello, W. Greenhalf and D. H. Palmer, Therapeutic developments in pancreatic cancer: current and future perspectives, Nat. Rev. Gastroenterol. Hepatol. 15(6) (2018) 333–348; https://doi.org/10.1038/s41575-018-0005-x
Search in Google Scholar Back to article
H. L. Kindler, A glimmer of hope for pancreatic cancer, N. Engl. J. Med. 379(25) (2018) 2463–2464; https://doi.org/10.1056/NEJMe1813684
Search in Google Scholar Back to article
N. Wang and Y. Feng, Elaborating the role of natural products-induced autophagy in cancer treatment: achievements and artifacts in the state of the art, Biomed. Res. Int. 2015 (2015) Article ID 934207 (15 pages); https://doi.org/10.1155/2015/934207
Search in Google Scholar Back to article
S. K. Saha and A. R. Khuda-Bukhsh, Molecular approaches towards development of purified natural products and their structurally known derivatives as efficient anti-cancer drugs: current trends, Eur. J. Pharmacol. 714(1-3) (2013) 239–248; https://doi.org/10.1016/j.ejphar.2013.06.009
Search in Google Scholar Back to article
I. Lohse, E. Wildermuth and S. P. Brothers, Naturally occurring compounds as pancreatic cancer therapeutics, Oncotarget 9(83) (2018) 35448–35457; https://doi.org/10.18632/oncotarget.26234
Search in Google Scholar Back to article
E. Kupeli Akkol, Y. Genc, B. Karpuz, E. Sobarzo-Sanchez and R. Capasso, Coumarins and coumarin-related compounds in pharmacotherapy of cancer, Cancers (Basel) 12(7) (2020) Article ID 1959; https://doi.org/10.3390/cancers12071959
Search in Google Scholar Back to article
A. Rasul, M. Khan, B. Yu, T. Ma and H. Yang, Xanthoxyletin, a coumarin induces S phase arrest and apoptosis in human gastric adenocarcinoma SGC-7901 cells, Asian Pac. J. Cancer Prev. 12(5) (2011) 1219–1223.
Search in Google Scholar Back to article
N. Renema, B. Navet, M. F. Heymann, F. Lezot and D. Heymann, RANK-RANKL signaling in cancer, Biosci. Rep. (2016) 36(4) Article ID e00366 (17 pages); https://doi.org/10.1042/BSR20160150
Search in Google Scholar Back to article
A. F. de Groot, N. M. Appelman-Dijkstra, S. H. van der Burg and J. R. Kroep, The antitumor effect of RANKL inhibition in malignant solid tumors – A systematic review, Cancer Treat. Rev. (2018) 62 18–28; https://doi.org/10.1016/j.ctrv.2017.10.010
Search in Google Scholar Back to article
M. Palafox, I. Ferrer, P. Pellegrini, S. Vila, S. Hernadez-Ortega, A. Urricoechea, F. Climent, M. T. Soler, P. Munoz, F. Vinals, M. Tometsko, D. Branstetter, W. C. Dougall and E. Gonzalez-Suarez, RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis, Cancer Res. (2012) 72(11) 2678–2688; https://doi.org/10.1158/0008-5472.CAN-12-0044
Search in Google Scholar Back to article
P. Pellegrini, A. Cordero, M. I. Gallego, W. C. Dougall, P. Munoz, M. A. Pujana and E. Gonzalez-Suarez, Constitutive activation of RANK disrupts mammary cell fate leading to tumorigenesis, Stem Cells (2013) 31(9) 1954–1965; https://doi.org/10.1002/stem.1454
Search in Google Scholar Back to article
S. J. Chanock, The paradox of mutations and cancer, Science 362(6417) (2018) 893–894; https://doi.org/10.1126/science.aav5697
Search in Google Scholar Back to article
F. Sanchez-Vega, M. Mina, J. Armenia, W. K. Chatila, A. Luna, K. C. La, S. Dimitriadoy, D. L. Liu, H. S. Kantheti, S. Saghafinia, D. Chakravarty, F. Daian, Q. Gao, M. H. Bailey, W. W. Liang, S.M. Foltz, I. Shmulevich, L. Ding, Z. Heins, A. Ochoa, B. Gross, J. Gao, H. Zhang, R. Kundra, C. Kandoth, I. Bahceci, L. Dervishi, U. Dogrusoz, W. Zhou, H. Shen, P.W. Laird, G. P. Way, C.S. Greene, H. Liang, Y. Xiao, C. Wang, A. Iavarone, A. H. Berger, T. G. Bivona, A. J. Lazar, G.D. Hammer, T. Giordano, L. N. Kwong, G. McArthur, C. Huang, A. D. Tward, M. J. Frederick, F. McCormick, M. Meyerson, E. M. Van Allen, A. D. Cherniack, G. Ciriello, C. Sander and N. Schultz, Oncogenic signaling pathways in the cancer genome atlas, Cell 173(2) (2018) 321–337; https://doi.org/10.1016/j.cell.2018.03.035
Search in Google Scholar Back to article
N. Renema, B. Navet, M. F. Heymann, F. Lezot and D. Heymann, RANK-RANKL signalling in cancer, Biosci. Rep. 36(4) (2016) Article ID e00366 (17 pages); https://doi.org/10.1042/BSR20160150
Search in Google Scholar Back to article
S. Rao, S. J. F. Cronin, V. Sigl and J. M. Penninger, RANKL and RANK: From mammalian physiology to cancer treatment, Trends Cell Biol. 28(3) (2018) 213–223; https://doi.org/10.1016/j.tcb.2017.11.001
Search in Google Scholar Back to article
S. Peters, P. Clezardin, I. Marquez-Rodas, D. Niepel and C. Gedye, The RANK-RANKL axis: an opportunity for drug repurposing in cancer? Clin. Transl. Oncol. 21(8) (2019) 977–991; https://doi.org/10.1007/s12094-018-02023-5
Search in Google Scholar Back to article
P. A. van Dam, Y. Verhoeven, X. B. Trinh, A. Wouters, F. Lardon, H. Prenen, E. Smits, M. Baldewijns and M. Lammens, RANK/RANKL signaling inhibition may improve the effectiveness of checkpoint blockade in cancer treatment, Crit. Rev. Oncol. Hematol. 133 (2019) 85–91; https://doi.org/10.1016/j.critrevonc.2018.10.011
Search in Google Scholar Back to article
Q. Wen, K. Luo, H. Huang, W. Liao and H. Yang, Xanthoxyletin inhibits proliferation of human oral squamous carcinoma cells and induces apoptosis, autophagy, and cell cycle arrest by modulation of the MEK/ERK signaling pathway, Med. Sci. Monit. 25 (2019) 8025–8033; https://doi.org/10.12659/MSM.911697
Search in Google Scholar Back to article
A. Rasul, M. Khan, B. Yu, T. Ma and H. Yang, Xanthoxyletin, a coumarin induces S phase arrest and apoptosis in human gastric adenocarcinoma SGC-7901 cells, Asian Pac. J. Cancer Prev. (2011) 12(5)1219–1223.
Search in Google Scholar Back to article
E. Gonzalez-Suarez and A. Sanz-Moreno, RANK as a therapeutic target in cancer, FEBS J 283(11) (2016) 2018–2033; https://doi.org/10.1111/febs.13645
Search in Google Scholar Back to article
A. von dem Knesebeck, J. Felsberg, A. Waha, W. Hartmann, B. Scheffler, M. Glas, J. Hammes, T. Mikeska, P. S. Yan, E. Endl and M. Simon, RANK (TNFRSF11A) is epigenetically inactivated and induces apoptosis in gliomas, Neoplasia (2012) 14(6) 526–534; https://doi.org/10.1596/neo.12360
Search in Google Scholar Back to article
M. Sisay, G. Mengistu and D. Edessa, The RANK/RANKL/OPG system in tumorigenesis and metastasis of cancer stem cell: potential targets for anticancer therapy, OncoTargets Ther. (2017) 10 3801–3810; https://doi.org/10.2147/OTT.S135867
Search in Google Scholar Back to article

Xanthoxyletin blocks the RANK/RANKL signaling pathway to suppress the growth of human pancreatic cancer cells

Abstract

Paradigm

My account